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Purpose: The primary objective of this study was to determine the
rate of pathological response after preoperative celecoxib and con-
current taxane-based chemotherapy in patients with cancer of the
esophagus and gastroesophageal junction.
Methods: Thirty-nine patients were enrolled in this single-arm,
phase II clinical trial. Patients were administered daily celecoxib in
combination with two to three cycles of carboplatin and paclitaxel
with preoperative intent. Levels of cyclooxygenase (COX)-2 expres-
sion in resected tumors were analyzed by immunohistochemistry
and correlated with clinical outcome measures. Postoperatively,
patients were administered daily celecoxib for 1 year or until
documented tumor recurrence.
Results: All patients received two to three cycles of chemotherapy
plus celecoxib 800 mg/d. Toxicities were as expected. A major
clinical response (complete response  partial response) was
noted in 22 patients (56%); six patients (15%) had a complete
clinical response. Thirty-seven patients underwent esophagec-
tomy. Five patients had a major pathological response (12.8%).
Four-year overall and disease-free survivals were 40.9% and
30.3%, respectively. Patients with tumors expressing COX-2
demonstrated a higher likelihood of a major clinical response
response (62% versus 50%) and an improved overall survival,
compared with patients with COX-2-negative tumors.
Conclusions: Preoperative celecoxib with concurrent chemotherapy
demonstrated sufficient effect on pathologic response to warrant
further study. Patients with tumors expressing COX-2 demonstrated
trends toward improved response to preoperative therapy and im-
proved overall survival compared with nonexpressors.
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Carcinoma of the esophagus is associated with a poorprognosis.1 Five-year survival rarely exceeds 15 to 20%
after surgery alone and is only modestly improved if surgery
is preceded by chemotherapy or chemoradiotherapy.2–11
Therefore, there is a clear need for the development of novel
treatment strategies to improve outcomes for patients with
esophageal cancer. Considerable data indicate that cycloox-
ygenase (COX)-2, an early response gene induced by various
mitogenic and inflammatory stimuli, is a potential therapeutic
target in a number of solid tumors including esophageal
cancer.12–26 For example, increased expression of COX-2 is
observed in 70 to 80% of esophageal adeno- and squamous
cell carcinomas of the esophagus, and COX-2 overexpression
is independently associated with significantly diminished
survival of patients with esophageal cancer.21,27–31 The neg-
ative impact of COX-2 expression on survival may be due, in
part, to its key role in intratumoral prostaglandin synthesis.
Prostaglandins are known tumor promoters that enhance
cancer growth by inhibition of apoptosis, and stimulation of
angiogenesis, and metastasis.17,20–22
Increased expression of COX-2 has also been noted to
occur in response to chemotherapy and radiotherapy, a phe-
nomenon that may potentially reduce the efficacy of cytotoxic
therapy.32–34 There is evidence from laboratory studies and
some clinical trials that inhibition of COX-2 activity may
enhance the cytotoxicity of chemotherapy agents and radia-
tion therapy.35–40 This study was designed to test the hypoth-
esis that celecoxib, administered at doses known to inhibit
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COX-2 function in vivo, would improve the pathological
response rate mediated by preoperative taxane-based chemo-
therapy in patients with potentially resectable cancer of the
esophagus and cardia. Additionally, we attempted to explore
the potential efficacy of adjuvant celecoxib in reducing or
delaying disease recurrence.
METHODS
Patients and Methods
From March 2003 to November 2005, 39 patients with
histologically confirmed carcinoma of the esophagus and
cardia were enrolled in a phase II, open-labeled, single-arm
trial. Patients were considered eligible if their clinical stage
was T2-T3/N0, T1-T3/ N1, or T1-T3/M1a-M1b (lymph). Patients
with clinical T4 tumors or metastases to distant organ sites
were not eligible. In all patients, pretreatment evaluation
included a complete history and physical examination,
computed tomography of the chest and upper abdomen, 18
fluoro-deoxyglucose positron emission tomography, and up-
per gastrointestinal endoscopy. Additionally, every patient
underwent esophageal endoscopic ultrasonography to deter-
mine malignant mural penetration and nodal involvement.
Lymph node metastases were identified on the basis of
standard echogenic criteria and/or fine needle aspiration cy-
tology of suspicious nodes. Additional eligibility criteria
included Karnofsky performance status 80%, acceptable
hepatic, renal, and bone marrow function, absence of signif-
icant cardiovascular disease, and willingness to abstain from
the use of steroidal or nonsteroidal antiinflammatory drugs
(other than low-dose acetylsalicylic acid or inhaled steroids)
for the duration of the study. The trial was approved by the
institutional review board, and an informed consent docu-
ment clearly describing the investigational nature of the
treatment plan and the ability to withdraw from the study at
anytime was signed by all patients. A separate institutional
review board approval was obtained to enable immunohisto-
chemical analysis of COX-2 expression in the resected tu-
mors. All clinical and pathological staging was based on the
sixth edition of the American Joint Committee on Cancer.41
Treatment Plan
Two to three cycles of paclitaxel and carboplatin
were administered 21 days apart. Paclitaxel was adminis-
tered as a 3-hour infusion at a dose of 200 mg/m2, followed
by a 1-hour infusion of carboplatin dosed to an area under
the curve of 6 by the Calvert formula. All patients were
premedicated by dexamethasone, diphenhydramine, and
H2-receptor antagonist.
Preoperative Celecoxib
Celecoxib was administered orally at a dose of 400 mg
twice daily starting 3 to 7 days before the first day of
chemotherapy and continued daily until the morning of sur-
gery. Compliance was determined by pill counts at each
follow-up visit, and patients were considered compliant if at
least 80% of the drug was taken.
Surgical Resection
Esophagectomy with reconstruction of the gastrointes-
tinal tract was planned to occur approximately 3 to 4 weeks
after the last cycle of chemotherapy provided that restaging
positron emission tomography and computed tomography
scanning showed no evidence of disease progression.
Adjuvant Celecoxib
Celecoxib was administered orally at 400 mg twice
daily starting no later than 3 months postoperatively provided
there was adequate wound healing. Celecoxib was to be
continued for 1 year or until documented tumor recurrence.
Compliance with adjuvant celecoxib was determined by pill
counts at each follow-up visit, and patients were considered
compliant if at least 80% of the drug was taken. Following
the publication of information regarding the frequency of
cardiovascular adverse events associated with long-term use
of celecoxib, all patients were required to sign a revised
consent form that clearly incorporated all new information
regarding adverse events possibly related to celecoxib, before
starting the adjuvant part of the trial.42
Criteria for Response
A major clinical response was defined as either a
complete or partial response, criteria for which are listed in
Table 1. Major pathological response was defined as either a
complete pathological response and/or minimal microscopic
residual disease in the resected specimen. Absence of any
tumor in the resected esophagus and lymph nodes on histo-
logical examination was considered a complete pathologic
response. Minimal microscopic residual disease was defined
as the presence of either microscopic foci of carcinoma in the
absence of a mass or scattered foci of microscopic carcinoma,
each not exceeding 2 mm in size, and in aggregate compris-
ing no more than 10% of the tumor mass.
Immunohistochemistry
Resected tissues were fixed in formalin, routinely pro-
cessed, and embedded in paraffin. Sections were cut at 4 m
and dehydrated through alcohol gradients. Antigen retrieval
was performed in a laboratory-grade microwave by boiling
and incubating for 20 minutes in Target Retrieval Solution
pH 9.0 (S2367; DAKO, Carpinteria, CA.) Endogenous per-
oxidase activity was inhibited by incubation in Dual Endog-
enous Enzyme Block (S2003; DAKO) for 10 minutes. Sec-
tions were then rinsed in a Tris-based wash buffer (S3006;
DAKO) and incubated at room temperature for 1 hour with a
TABLE 1. Criteria for Clinical Response
Complete
response
Disappearance of all clinical evidence of tumor on
endoscopic examination and absence of activity on
restaging PET scanning
Partial
response
Fifty-percent reduction in the length of the primary
tumor as determined by endoscopy
Stable disease Less than 50% reduction in endoscopic tumor length
Disease
progression
A 25% or greater increase in endoscopic tumor length
PET, positron emission tomography.
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Cox-2-specific murine monoclonal antibody (clone CX-294,
M3617; DAKO) diluted 1:75. After washing in Tris buffer,
samples were incubated with horseradish peroxidase-conju-
gated secondary antibody (EnvisionFlex/HRP; DAKO) for 1
hour at room temperature, rinsed in Tris buffer, and incubated
in 3,3-diaminobenzidine substrate buffer (DAKO) for 5
minutes at room temperature. Specimens were rinsed in H2O
and counterstained with hematoxylin, dehydrated, and
mounted. Colon carcinoma sections were used as positive
controls. To confirm the specificity of results, additional
sections were processed for staining without incubation with
the primary anti-COX-2 antibody.
COX-2 expression in tumor tissues was scored using a
0 to 4 scale, with no tumor cells stained  0, and 1 to 25%,
26 to 50%, 51 to 75%, and more than 75% of positive cells
being scored as 1, 2, 3, and 4, respectively. Results of
preliminary histopathologic analysis were independently ver-
ified in a blinded manner by a second anatomic pathologist.
Statistical Considerations
Sample Size
The primary objective of this phase II trial was to
determine the rate of major pathologic response, as previ-
ously defined, in the resected specimens of patients receiving
preoperative paclitaxel/carboplatin/celecoxib. A Simon two-
stage minimax design was applied to test the efficacy of the
combination regimen.43 Thirty patients were to be enrolled in
the first stage, and if one or no major pathologic responses
were observed, the trial would be terminated early and de-
clared to have a negative result. If two or more major
pathologic responses were observed, then an additional nine
patients (total 39) were to be enrolled. If on completion of the
trial, five or more major pathologic responses were observed
(13%) out of the 39 enrolled patients, the treatment would
be declared effective and worthy of further study. This design
yielded a 0.95 probability of a positive result (beta error 
0.05) if the true major pathologic response rate was 22%
and a 0.95 probability of a negative result (alpha error 
0.05) if the true major pathologic response rate was 5%.
With a total sample size of 39 patients, a 95% confidence
interval (CI) could be constructed to be within 11% of the
true major pathologic response rate.
Statistical Analysis
Descriptive statistics were calculated for baseline de-
mographic and clinical/prognostic characteristics. The 2 test
or Fisher’s exact test were used to assess the univariate
association between categorical predictor variables and cate-
gorical outcome variables of interest (i.e., depending on the
expected cell frequencies in the cross-tabulation analyses).
The two-sample t test or the nonparametric Wilcoxon-rank
sum test were used, as appropriate, to assess the univariate
association between categorical predictor variables and con-
tinuous outcome variables of interest. Kaplan-Meier survival
analysis was performed to evaluate disease-free survival
(DFS) and overall survival (OS) for all study patients, and the
log-rank test was used to compare DFS/OS between levels of
clinical/prognostic factors of interest. DFS was defined as the
time from first treatment day (i.e., date of first treatment with
celecoxib) until tumor recurrence or death from any cause (or
until date of last follow-up if no recurrence/death). OS was
defined as the time from first treatment day (i.e., date of first
treatment with celecoxib) until death from any cause (or until
date of last follow-up if no death). All DFS and OS analyses
were based on an intention-to-treat analysis (i.e., all patients
were analyzed regardless of full compliance with celecoxib
treatment). Median follow-up time for the study group was
computed based on the surviving patients. Given the small
sample size in the study, no multivariate analysis for DFS or
OS could be performed because the number of recurrences/
deaths in the cohort would not allow for multivariate models
with stable estimates for the model coefficients. All p values
were two sided with statistical significance evaluated at the
0.05 alpha level. Ninety-five percent CIs were calculated to
assess the precision of the obtained estimates. All analyses
were performed in SAS Version 9.2 (SAS Institute, Inc.,
Cary, NC) and STATA Version 11.0 (StataCorp, College
Station, TX).
RESULTS
Thirty-nine patients were enrolled in this single-arm
phase II trial. Patient’s characteristics are listed in Table 2.
Median age was 63 years, and the majority had adenocarci-
noma. Approximately two thirds of patients had either stage
III or IV disease. Approximately 87% were men; and 72% of
all patients in the study were smokers.
TABLE 2. Patient Characteristics (n  39)
Patients
Median age 63 (38–76)
Males 34
Females 5
Smoking status
Current 9
Former 19
Never 11
Clinical stage
IIA (T2N0/T3N0) 9 (3/6)
IIB (T2N1) 4
III (T3N1) 20
IVA (T3N0M1a/T4N1M1a) 2
IVB (T1N1M1ba/T3N1M1ba) 4 (1/3)
Cell type
Adenocarcinoma 33
Squamous cell carcinoma 6
Postsurgical staging (n  37)
yp 0 1
yp I 1
yp IIA (T2N0M0/T3N0M0) 9 (3/6)
yp IIB (T0N1M0/T2N1M0) 6 (1/5)
yp III (T3N1M0/T4NxM0) 16 (15/1)
yp IVA (T3N1M1a) 1
yp IVB (T1N0M1b/T3N1M1b/T4N1M1b) 5 (1/3/1)
a The clinical M1b classification referred to nonregional lymph node metastases.
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Preoperative Therapy
All patients received the per-protocol planned courses
of chemotherapy. Twenty-eight patients received two cycles,
and after a protocol amendment, 11 patients received three
cycles. All patients completed the prescribed preoperative
celecoxib treatment without incident.
Response to Induction Therapy
A major clinical response, as previously defined, was
noted in 22 patients (56%). Six patients (15%) had a complete
clinical response, with no clinical or histological evidence of
carcinoma seen at endoscopy.
Surgical Treatment
Two patients were explored but not resected due to
previously unsuspected airway invasion. An esophagectomy
with mediastinal and abdominal lymph node dissection was
performed in all remaining patients. Twenty patients had
additional dissection of the cervical and superior mediastinal
lymph nodes. The median number of resected lymph nodes
was 30. Postsurgical staging is presented in Table 2. There
was no operative or hospital mortality.
Pathological Response
Five patients had a major pathological response as
previously defined (12.8%; 95% CI: 4.8–28.2%), which re-
sulted in the primary end point of the study being met. A
complete pathological response was noted in one patient, and
four patients had minimal residual disease. Thirty-two pa-
tients had no discernable treatment effect on pathological
examination, whereas two patients had disease progression
precluding resection.
Treatment-Related Toxicity
There were no treatment-related deaths. Toxicities at-
tributable to preoperative treatment are listed in Table 3. Five
patients (15%) had pulmonary emboli, and 13 (33%) had
atrial fibrillation in the perioperative period.
Adjuvant Celecoxib
Nine patients received adjuvant celecoxib treatment for
less than 6 months, and 19 patients received adjuvant cele-
coxib for 6 months or more. Two patients who had been on
celecoxib for 1 month and 8 months developed deep vein
thrombosis and shortly thereafter exhibited recurrent disease.
Eleven patients did not receive adjuvant celecoxib, of whom
two patients developed deep vein thrombosis and subsequent
disease recurrence.
Survival
Median follow-up for surviving patients was 64 months
(range: 39.0–67.2 months). Four-year OS and DFS were
40.9% (95% CI  25.5–55.7%) and 30.3% (95% CI 
16.7–45.0%), respectively (Figures 1 and 2). Corresponding
median OS and DFS were 31.1 months (95% CI 18.5–59.4
months) and 24.0 months (95% CI  13.0–37.7 months),
respectively. There was a nonsignificant trend for improved
OS in patients who had a major clinical response (CR  PR;
N  22) compared with patients who had minimal response
FIGURE 1. Overall survival (OS) for the entire cohort. N 
39 patients, 25 deaths. Median OS time  31.1 months
(95% confidence interval [CI]  18.5–59.4). Four-year OS 
40.9% (95% CI  25.5–55.7%).
FIGURE 2. Disease-free survival (DFS) for the entire cohort.
N  39 patients, 28 recurrences or deaths. Median DFS 
24.0 months (95% confidence interval [CI]  13.0–37.7
months). Four-year DFS  30.3% (95% CI  16.7–45.0%).
TABLE 3. Neoadjuvant Grade 3 and 4 Events (n  39)
Adverse Events Grade 3 Grade 4
Musculoskeletal
Myalgia 2 0
Constitutional
Fatigue 1 0
Cardiovascular
Hypotension 1 0
Atrial fibrillation 1 0
Syncope 2 0
Preoperative hematological
Neutropenia 7 7
Neutropenic fever 3 2
Anemia 2 0
Thrombocytopenia 2 0
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or stable disease (median OS  35.4 months versus 30.7
months, respectively, p  0.20). Similar results were ob-
served for improvement in DFS among patients with a major
clinical response versus all others (median DFS  25.4
months versus 18.7 months, respectively, p  0.04). There
was no difference in either OS or DFS between patients who
received adjuvant celecoxib for less than 6 months versus 6
months or more (p  0.75 for OS and p  0.78 for DFS).
COX-2 Immunohistochemistry
Tumor specimens were available from 35 patients for
immunohistochemistry analysis of intratumoral COX-2 ex-
pression. Fourteen (40%) had no detectable COX-2 protein
expression, whereas 21 (60%) had at least 10% of tumor cells
showing cytoplasmic COX-2 staining. Patients who had
COX-2 expressing tumors were more likely to have a major
clinical response (13/21, 62%) than those with COX-2-neg-
ative tumors (7/14; 50%); however, the difference was not
statistically significant Interestingly, tissue was available for
COX-2 immunohistochemistry in three of the four patients
who had microscopic residual disease on pathological exam-
ination; all three patients had COX-2 protein expression in
their residual tumors. Furthermore, there was a nonsignificant
trend favoring improved OS among patients whose tumors
expressed COX-2 compared with nonexpressors. Specifi-
cally, median and 4-year OS survival were 38.1 months and
47.6%, respectively, in patients whose tumors expressed
COX-2, versus 26.2 months and 21.4% for the nonexpressors
(p  0.24) (Figure 3). Median and 4-year DFS were also
slightly higher for COX-2 expressors (23.7 months and
33.3%, respectively) versus nonexpressors (17.8 months and
21.4%, respectively, p  0.42).
DISCUSSION
Despite evidence that chemotherapeutic agents includ-
ing taxanes are potent inducers of COX-2 and that abrogation
of COX-2 activity may potentially enhance their cytotoxic-
ity,32–34,40 trials examining the efficacy of COX-2 inhibitors
administered in conjunction with chemotherapy or chemora-
diotherapy have yielded mixed and mostly disappointing
results.35,38,44–46 For example, in several phase II trials, the
addition of celecoxib at 800 mg/d to 5-flourouracil and either
irinotecan or oxaliplatin resulted in no improvements in
response or survival in patients with metastatic colorectal
cancer.44–46 In contrast, celecoxib enhanced the effects of
preoperative taxane-based chemotherapy in patients with
early-stage lung cancer.38 These conflicting results may be
due to multiple factors including potentially complex phar-
macodynamic interactions between celecoxib and different
chemotherapeutic agents, the magnitude of intratumoral
COX-2 expression, and ABC transporter expression.47–50 The
significance of COX-2 expression in tumors treated by cele-
coxib was elegantly shown in a randomized phase II trial
reported by Edelman et al.51 Patients with advanced lung
cancer treated with gemcitabine and carboplatin were ran-
domly assigned to receive celecoxib, the lipoxygenase inhib-
itor zeluton, or both of these drugs. In a prospectively planned
subset analysis, patients with increased intratumoral COX-2
expression who were treated with celecoxib had significantly
improved survivals compared with patients with COX-2-
positive tumors not receiving celecoxib. Importantly, patients
with tumors lacking COX-2 expression who received cele-
coxib had significantly worse survivals than those with COX-
2-negative tumors who were not treated with celecoxib.
Despite the relatively small sample size in the current
trial, it is interesting to note that celecoxib seemed to have a
beneficial effect in terms of response and survival only in
patients whose tumors expressed COX-2. Although the re-
sults fell short of statistical significance, patients with COX-
2-positive tumors were more likely to experience a major
clinical response and improvement in overall and DFS than
those with COX-2-negative tumors. It is also of interest that
all three patients with microscopic residual disease from
whom tissue was available for IHC had elevated COX-2
expression in their tumors.
Although the trial met its primary objective of achiev-
ing complete pathological response and/or minimal residual
disease in 13% of patients (i.e., 5 major pathologic re-
sponses out of 39 patients), several cautionary notes are
warranted before further evaluation of celecoxib therapy in
esophageal cancer. First, the data regarding the predictive
benefit of COX-2 expression were derived from an unplanned
posthoc analysis and was not a prespecified end point in the
trial design. Furthermore, by necessity, COX-2 analysis was
performed on posttreatment resected tissues rather than pre-
treatment biopsies; hence this observation will need to be
verified in a larger trial with pre/posttreatment COX-2 ex-
pression as specified end points. Although our COX-2 ex-
pression may have been induced by chemotherapy, the hy-
pothesis of the study examining the effect of abrogation of
COX-2 activity on response would likely be unaffected by
FIGURE 3. Overall survival (OS) comparison between ex-
pressors and nonexpressors of cyclooxygenase (COX)-2. No
expression: N  14 patients, 11 deaths. Median OS time 
26.2 months (95% confidence interval [CI]  12.1–43.7).
Four-year OS  21.4% (95% CI  5.2–44.8%). Expression:
N  21 patients, 12 deaths. Median OS time  38.1
months (95% CI  17.0, not estimated). Four-year OS 
47.6% (95% CI  25.7–66.7%).
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such induction. Second, the preoperative administration of
celecoxib in this trial was associated with a higher than
expected incidence of venous thromboembolic adverse events
despite standard perioperative prophylactic measures.52 We
did not observe a similar adverse events profile in a previous
trial of preoperative celecoxib in patients with early stage
lung cancer.38 Further trials evaluating the role of celecoxib
in patients undergoing esophagectomy or other major abdom-
inal surgery should include intensification of prophylactic
measures to decrease the propensity for venous thromboem-
bolic events and careful perioperative monitoring of cardiac
arrhythmias. In this regard, it is important to point out that in
the current trial, patients continued to take celecoxib up to the
day of surgery. It is conceivable that stopping treatment at
least a week before any planned surgical intervention might
have blunted some of the prothrombotic effects of COX-2
inhibition. Finally, although this trial was not designed to
address the benefit of adjuvant celecoxib, we were unable to
detect a signal suggesting efficacy of the COX-2 inhibitor in
either preventing or delaying cancer recurrence.
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